Trial intelligence / Profile preview

BGB-3111 in relapsed or refractory Waldenström macroglobulinemia

CTR20170208Phase 2Completed

Sponsor
BeiGene
Start
Apr 2017
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
Countries
1
01

Overview

A Phase 2 trial of zanubrutinib in Waldenström macroglobulinemia (WM), sponsored by BeiGene. Started Apr 2017; status: completed.

02

Drugs

zanubrutinib
03

Conditions

Waldenström macroglobulinemia (WM)

Beyond the preview

Go deeper on CTR20170208.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on CTR20170208.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call